Miriam first in New England to do completely laparoscopic robotic-assisted surgery for bladder cancer

October 12, 2016

PROVIDENCE, R.I. - The Minimally Invasive Urology Institute (MIUI) at The Miriam Hospital is now performing a completely laparoscopic surgery for the treatment of bladder cancer.

The procedure - robotic-assisted laparoscopic radical cystectomy with intracorporeal urinary diversion - can be used to remove the bladder, pelvic lymph nodes and prostate in men, and the bladder, uterus and fallopian tubes in women. The surgery concludes with removing a piece of bowel and using it to create a urinary diversion, or way for urine to leave the body in the absence of the bladder. The entire surgery is performed with an intracorporeal approach, meaning completely laparoscopically within the body, versus traditional open surgery.

Previously, the surgery was performed at The Miriam Hospital with a seven- to 10-centimeter incision at the belly button, and the urinary diversion was created through this incision, outside the body. Most other institutions still perform the surgery with a large incision in an open surgical approach. In addition to featuring smaller incisions, the minimally invasive intracorporeal approach offers improved patient outcomes, including a lower complication rate and shorter hospital stay, according to the International Robotic Cystectomy Consortium.

Dragan Golijanin, M.D., director of genitourinary oncology at The Miriam and Rhode Island hospitals and co-director of the MIUI, is among the first 11 urologists nationwide, and the only physician in New England, to have successfully performed a robotic cystectomy with intracorporeal urinary diversion. The first hospital in Southern New England to perform a robotic-assisted procedure, The Miriam has completed more than 2,000 urologic robotic-assisted surgeries since 2006.

"In being able to perform this difficult surgery laparoscopically from beginning to end, we are able to remain on the leading edge of bladder cancer treatments by offering patients the latest, most innovative care available. The result is improved outcomes for our patients. This further demonstrates our commitment to advanced urologic treatments," said Golijanin.

Cancer of the urinary bladder is the fifth most common cancer in Rhode Island, and the sixth most common in the United States. Bladder cancer also has the highest recurrence rate of any form of cancer. The most common symptom is blood in the urine, and a patient who experiences this should contact his or her physician immediately. Other symptoms include frequency, urgency, or pain while urinating.
About The Miriam Hospital

The Miriam Hospital is a 247-bed, not-for-profit teaching hospital affiliated with The Warren Alpert Medical School of Brown University. It offers expertise in cardiology, oncology, orthopedics, men's health, and minimally invasive surgery and is home to the state's first Joint Commission-certified Stroke Center and robotic surgery program. The first in Southern New England to perform robotic surgery and the only hospital in Rhode Island that offers a kidney stone center, The Miriam Hospital received more than $23 million in external research funding last year. It treats a range of urologic conditions and is one of three New England hospitals to offer blue-light cystoscopy for the diagnosis and treatment of bladder cancer. Named 2015-16 best regional hospital in Rhode Island and the Providence metro area by U.S. News & World Report, The Miriam Hospital has been awarded Magnet Recognition for Excellence in Nursing Services five times and is a founding member of the Lifespan health system. Follow us on Facebook, Twitter (@MiriamHospital and Pinterest.


Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.